oncolog-hematolog
ro
hematologie
Chirurgie
Clinica de
Chir.Plastica
Chirurgie
oncologica
recuperare
2%
2%
2%
2%
Balneofizioterapie
2%
Ginecologie
2%
Urologie
3% ORL
2%
Neurologie
3%
Chirurgie toracica
Medicala
3%
31%
Pneumoftiziologie
5%
Dializa
5%
Cardiologie
5%
Gastroenterologie
10% Figura 30.
Neurochirurgie
Nefrologie
Profilul clinicilor care
10%
10% au formulat suspiciunea
de MM
Sindrom anemic
Discopatie lombara. Sciatalgii
2%2%
1%
Tumora toracica
2%
Gamapatie monoclonala
8%
18%
GNC.IRC
2%
Radiculonevrita
2%
Parapareza
Reumatism degenerativ
2% 13%
Tumora fronto-parietala
Discartroza cervico-dorso-lombara
2%
Gonalgie stanga
2% HDS
Hipoplazie medulara
2%
Neoplasm digestiv
12%
3%
Sindrom hepatosplenomegalic
3% Sindrom paraneoplazic
2%
Sindrom Raynaud
4%
5%
5%
Sindrom subfebril prelungit
Figura 31.
SMPC-PV
Structura diagnosticelor
Neoplasm pulmonar
de “împrumut”
Bibliografie
1. Bergsagel P.L. Prognostic factors in multiple myeloma: it’s in the genes. Clin Cancer stem cell transplantation: t(4;14) is the most relevand adverse prognostic factor,
Res 2003; 9:533-4. whereas RB deletion as a unique abnormality is not associated with adverse prog-
2. Bataille R., Jego G., Robillard N. et al. The phenotype of normal, reactive and ma-
nosis. Leukemia 2007; 21:143-50.
lignant plasma cells. Identification of „many and multiple myeloma” and of new
7. San Miguel J.F., Garcia-Sanz R. Prognostic features of multiple myeloma. Best Pract
targets for myeloma therapy. Haematologica 2006; 91: 1234-64.
Res Clin Haematol 2005; 18:569-83.
3. Robillard N., Pellat-Deceunynck C., Bataille R. Phenotypic characteriyation of the
8. Blade J., Kyle R.A., Greipp P.R. Presenting features and prognosis in 72 patients with
human myeloma cell growth fraction. Blood 2005; 105: 4845-8.
multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93:345-
4. Kumar S., Rajkumar S.V., Kimlinger T. et al. CD45 expression by bone marrow
plasma cells in multiple myeloma: clinical and biological correlations. Leukemia
51.
2005; 19:1466-70.
9. Moulopoulos L.A., Gika D., Anagnostopoulos A. et al. Prognostic significance of
5. Avet-Loiseau H., Attal M., Moureau P. et al. Genetic abnormalities in myeloma: teh
magnetic resonance imaging of bone marrow in previously untreated patients
experience of the Intergroupe Francophone du Myélome. Blood 2007; 109:3489-
with multiple myeloma. Ann Oncol 2005; 16:1824-8.
95.
10. Knobel R.A., Therneau T.M., Rajkumar S.V. et al. A long-term study of prognosis
6. Gutierrey N.C., Castellanos M.V., Moureau P. et al. Prognostic and biological im- plasmacytoma of the bone: a multicenter rare cancer network study. BMC Cancer
plications of genetic abnormalities in multiple myeloma undergoing autologous 2006; 6:118.
pag. 64
Nr. 7 (2)/2009
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68